Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research note released on Wednesday morning. The firm issued a sell rating on the biotechnology company’s stock.

Separately, Roth Capital downgraded Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Stock Performance

Shares of CYCC opened at $0.32 on Wednesday. The stock has a market capitalization of $2.00 million, a P/E ratio of -0.03 and a beta of 0.38. Cyclacel Pharmaceuticals has a 1 year low of $0.31 and a 1 year high of $4.00. The company’s fifty day moving average is $0.51 and its two-hundred day moving average is $1.05.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.36. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. Sell-side analysts predict that Cyclacel Pharmaceuticals will post -1.95 EPS for the current year.

Hedge Funds Weigh In On Cyclacel Pharmaceuticals

A hedge fund recently bought a new stake in Cyclacel Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned 9.18% of Cyclacel Pharmaceuticals as of its most recent SEC filing. 23.58% of the stock is currently owned by institutional investors.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.